Cephalon, Cima Sue Mylan To Block Generic Fentora

Law360, New York (February 28, 2011, 2:34 PM EST) -- Cephalon Inc. and Cima Labs Inc. launched a patent infringement suit against Mylan Inc. in Delaware on Friday, targeting the company over its attempts to market a generic version of Cephalon's cancer painkiller drug Fentora.

Douglas E. McCann of Fish & Richardson PC lodged the suit in the U.S. District Court for the District of Delaware, accusing the generic-drug maker of infringing U.S. Patent Numbers 6,200,604 and 6,974,590.

According to the suit, both patents — which Cima owns and licenses exclusively to Cephalon — cover methods...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.